Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziv-aflibercept in Retinal Diseases with Poor Vision
NCT02173873Phase 1Unknown
- Sponsor
- Rafic Hariri University Hospital
- Start
- Jun 2014
- Primary completion
- Sep 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aflibercept in exudative macular degeneration, central retinal vein occlusion (CRVO) and diabetic macular edema (DME), sponsored by Rafic Hariri University Hospital. Primary endpoints: Safety monitoring by OCT and visual acuity at 2 years and OCT retinal structure at 2 years. Status: unknown.
02
Drugs
aflibercept
03
Conditions
exudative macular degenerationcentral retinal vein occlusion (CRVO)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02173873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173873.